AFFILIATIONS
1 1- Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy
2 20- EBMT, Sorbonne University, Hôpital Saint Antoine, Department of Hematology, Paris, France, Paris, France
3 1- Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy
4 1- Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy
5 2- University of Muenster, Muenster, Germany
6 3- Hannover Medical School, Hannover, Germany
7 4- Division of Stem Cell Transplantation and Cellular Immunotherapy, University Hospital Schleswig-Holstein, Kiel, Kiel University, Kiel, Germany, Kiel, Germany
8 5- University Medical Center Mainz, Mainz, Germany
9 6- University Hospital Erlangen, Erlangen, Germany
10 7- University of Freiburg, Freiburg, Germany
11 8- University Hospital | Essen, Essen, Germany
12 9- University Regensburg, Regensburg, Germany
13 10- Goethe University Frankfurt, University Hospital, Dept of Medicine 2, Frankfurt, Germany, Frankfurt, Germany
14 11- IRCCS San Raffaele Hospital Scientific Institute, Milan, Italy
15 12- Klinikum Grosshadern, Grosshadern, Germany
16 13- Charles University Hospital Pilsen, Pilsen, Czech Republic
17 14- Universitaetsklinikum Goettingen, Goettingen, Germany
18 15- Augsburg University Hospital, Augsburg, Germany
19 16- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
20 17- Antwerp University Hospital, Antwerp, Belgium
21 18- Universitaets klinikum Dresden, Dresden, Germany
22 19- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
23 20- EBMT, Sorbonne University, Hôpital Saint Antoine, Department of Hematology, Paris, France, Paris, France
24 20- EBMT, Sorbonne University, Hôpital Saint Antoine, Department of Hematology, Paris, France, Paris, France
25 Hematology Division, Department of Internal Medicine, University of Patras, Medical School, Patras, Patras, Greece
26 22- Ematologia, Trapianto e Terapia Cellulare, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy., Ancona, Italy
27 23- Department of Hematology, University of Liege, Liege, Belgium, Liege, Belgium
28 24- Hematology Department, Hospital Universitari i Politècnic La Fe; Department of Medicine, University of Valencia, València, Spain, Valencia, Spain
29 20- EBMT, Sorbonne University, Hôpital Saint Antoine, Department of Hematology, Paris, France, Paris, France
ABSTRACT
Background: Fludarabine–melphalan (FluMel) is a widely used reduced-intensity conditioning regimen for adults with acute myeloid leukemia (AML). As graft-versus-host disease (GvHD) remains a major determinant of post-transplant outcomes, optimisation of GvHD prophylaxis is a clinical priority. Although post-transplant cyclophosphamide (PTCy) has been increasingly adopted beyond the haploidentical setting, its comparative efficacy and safety versus ATG-based prophylaxis after FluMel conditioning remain uncertain.
Aims: To compare transplant outcomes of PTCy- and ATG-based GvHD prophylaxis in adults with AML undergoing first allogeneic HSCT (allo-HSCT) following FluMel-based conditioning.
Methods: Adult patients with AML in complete remission undergoing first allo-HSCT between 2010 and 2023 after FluMel-based conditioning were identified from the EBMT registry. Bone marrow and peripheral blood grafts from matched sibling, matched unrelated, mismatched unrelated, and haploidentical donors were included. Patients receiving cord blood transplantation or had previous autologous or allogeneic transplant were excluded. Endpoints included overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM), and acute and chronic GvHD. Multivariable Cox and Fine-Gray regression models adjusted for donor type, graft source, Karnofsky performance status, patient age, donor-recipient CMV serostatus, female donor-to-male recipient, transplant year, and transplant center.
Results: A total of 2,259 adults with AML undergoing first FluMel-conditioned allo-HSCT between 2010 and 2023 were included, of whom 498 (22.0%) received PTCy and 1,761 (78.0%) ATG-based GvHD prophylaxis. Median patient age was 59.5 years, 53.6% were male, 84.2% underwent transplantation in CR1, and peripheral blood was the predominant graft source (95.4%). Donors included matched unrelated (54.3%), haploidentical (16.4%), matched sibling (15.0%) and mismatched unrelated donors (14.4%). Median follow-up was 3.9 years. PTCy recipients more frequently underwent transplantation in recent years, received haploidentical grafts, and myeloablative conditioning (MAC). At 2 years, OS was 64.8% with PTCy versus 63.6% with ATG, LFS was 58.7% versus 58.1%, relapse incidence was 19.4% versus 17.4%, and NRM was 22.0% versus 24.6%, respectively. Extensive chronic GvHD occurred less frequently after PTCy (2.8% vs 7.1%). After multivariable adjustment, GvHD prophylaxis was not associated with OS, LFS, GRFS, relapse incidence, acute GvHD or overall chronic GvHD. However, PTCy was independently associated with a higher risk of NRM (HR 1.72, 95% CI 1.24–2.39; P=0.001), despite a significantly lower risk of extensive chronic GvHD (HR 0.39, corresponding to ATG vs PTCy HR 2.59, 95% CI 1.15–5.84; P=0.022). Older age, Karnofsky score <90 and haploidentical donor type were also independently associated with higher NRM.
Conclusions: Among adults with AML undergoing FluMel-conditioned allo-HSCT, PTCy- and ATG-based GvHD prophylaxis were associated with comparable disease control and survival. PTCy was associated with a lower incidence of extensive chronic GvHD but also with higher non-relapse mortality, resulting in no overall survival advantage in this retrospective analysis. Given the substantial differences in donor type, transplant characteristics and treatment era between groups, residual confounding cannot be excluded despite multivariable adjustment. Therefore, these findings should be interpreted cautiously and do not establish a causal relationship between GvHD prophylaxis strategy and non-relapse mortality. Prospective studies are warranted to define the optimal prophylaxis approach after FluMel conditioning.